2025-01-24 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Analysis Report

**1. Performance Comparison & Company Overview:**

Colgate-Palmolive Co (CL) is a multinational consumer goods company specializing in oral hygiene products, personal care items, and veterinary products.

The cumulative return for CL is 35.11%, significantly underperforming the S&P 500 (VOO) which achieved a 122.83% return over the same period.  The difference is a substantial -87.7 percentage points.  This places CL at the lowest percentile (0%) based on historical data relative to the S&P 500's performance.


**Alpha and Beta Analysis:**

The provided data shows inconsistent performance relative to the market (Beta fluctuates around 0.72, indicating lower volatility than the market, but not a consistent outperformance) and positive Alpha in some years, indicating periods of outperformance. However, the overall trend suggests underperformance against the benchmark. The CAGR (Compound Annual Growth Rate) fluctuates, suggesting inconsistent growth.  Maximum Drawdown (MDD) varies considerably, highlighting significant risk periods.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 12.0% | 12.6% | -15.0% | 0.1 | 72.0 |
| 2016-2018  | -7.0% | 13.8% | -22.0% | 0.1 | 72.0 |
| 2017-2019  | 9.0% | 13.8% | -23.0% | 0.1 | 72.0 |
| 2018-2020  | 21.0% | 21.5% | -13.0% | 0.1 | 72.0 |
| 2019-2021  | 41.0% | 21.5% | -39.0% | 0.1 | 72.0 |
| 2020-2022  | 16.0% | 21.5% | 9.0% | 0.1 | 72.0 |
| 2021-2023  | -6.0% | 16.2% | -30.0% | 0.1 | 72.0 |
| 2022-2024  | 10.0% | 16.2% | -12.0% | 0.1 | 72.0 |
| 2023-2025  | 14.0% | 18.3% | -60.0% | 0.1 | 72.0 |


**2. Recent Price Movement:**

* **Closing Price:** $87.91
* **5-Day Moving Average:** $87.99
* **20-Day Moving Average:** $88.73
* **60-Day Moving Average:** $91.76

The price is slightly below all three moving averages, suggesting a potential downward trend in the short-term.  The recent price increase of $0.41 is relatively small and doesn't indicate a significant reversal.

**3. Technical Indicators & Expected Return:**

* **RSI:** 34.57 (Below 30, indicating oversold conditions)
* **PPO:** 0.19 (Positive, suggesting bullish momentum, but weak)
* **Relative Strength Index (20-day):** -1.5 (Short-term downward trend)
* **Expected Return (2+ years):** -4807.5% (This is an extraordinarily negative value and highly improbable.  The data source for this figure needs to be reviewed and verified. It likely contains an error.)

The RSI suggests the stock may be oversold, offering a potential buying opportunity for long-term investors. However, the low PPO and negative relative strength suggest caution. The extremely negative expected return requires further investigation.


**4. Recent Earnings Analysis:**

The earnings data shows relatively stable revenue around $5B per quarter, but EPS shows slight increases and inconsistencies.  There is a duplication of the October 2024 data.  Further data cleaning and verification are needed.

| Date       | EPS | Revenue       |
|------------|-----|---------------|
| 2024-10-25 | 0.9 | $5.03B        |
| 2024-07-26 | 0.89 | $5.06B        |
| 2024-04-26 | 0.83 | $5.07B        |
| 2023-10-27 | 0.86 | $4.92B        |
| 2024-10-25 | 0.86 | $4.92B        |


**5. Financial Information:**

The financial data reveals relatively consistent revenue but significant fluctuations in profitability metrics (Profit Margin, ROE, and Equity). Negative equity in 2023-09-30 and extremely high ROE values in Q2 2024 require careful analysis and investigation to identify the root causes.  These figures could indicate accounting irregularities or data errors.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $5.03B | 61.08% |
| 2024-06-30 | $5.06B | 60.62% |
| 2024-03-31 | $5.07B | 60.00% |
| 2023-12-31 | $4.95B | 59.60% |
| 2023-09-30 | $4.92B | 58.54% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-09-30 | $0.43B | 169.43% |
| 2024-06-30 | $0.12B | 594.31% |
| 2024-03-31 | $0.23B | 296.96% |
| 2023-12-31 | $0.61B | 117.90% |
| 2023-09-30 | $-0.01B | -7866.67% |


**7. Overall Analysis:**

Colgate-Palmolive (CL) shows significant underperformance against the S&P 500, with inconsistent growth and high volatility. While some technical indicators suggest potential oversold conditions, the extremely negative projected return and inconsistencies in financial data require thorough investigation.  The unusually high and low ROE values and the negative equity figure necessitate a review of the underlying data for accuracy and potential errors.  Before making any investment decisions, a deeper dive into the company's financial statements and industry comparisons is crucial.  The substantial discrepancies and seemingly erroneous data raise serious concerns about the reliability of the provided information.
